MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer ("CDO") and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of... Read More